

<i>Highly Specialised Technologies (HST)</i>	<i>Date of HST Release</i>	<i>Adherence of local formulary to NICE</i>	
		<i>Included on the Trust Formulary for this indication</i> <i>Yes OR</i> <i>No</i>	<i>Reason provided if "No"</i>
<b>2022-23</b>			
HST19 - Elosulfase alfa for treating mucopolysaccharidosis type 4A	20/04/2022	<b>No</b>	Not applicable to CWFT - not commissioned
HST20 - Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over	05/05/2022	<b>No</b>	Not applicable to CWFT - not commissioned
HST21 - Setmelanotide for treating obesity caused by LEPR or POMC deficiency	06/07/2022	<b>No</b>	Not applicable to CWFT - not commissioned
HST22 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene	22/02/2023	<b>No</b>	Not applicable to CWFT - not commissioned
HST23 Asfotase alfa for treating paediatric-onset hypophosphatasia	01/03/2023	<b>No</b>	Not applicable to CWFT - not commissioned